RxDoctor Payments Data

Jennifer Davis, MD

Interventional Cardiology · Green Bay, WINPI 1801159264

Payments from drug & device makers

$3,034in general payments, 2019–2025

Across 71 payments — averaging $42.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Edwards Lifesciences$886
  • Boston Scientific$434
  • Medtronic$248
  • Abbott$157
  • E.r. Squibb & Sons, L.L.C.$103
  • plus $203 from 8 others

What the payments were for

  • Travel & lodging$61720%
  • Food & beverage$2,37578%
  • Gifts$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,034 in reported general payments places this provider in the 35th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$96,666
Medicare patients
929
Services billed
1,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban723$784,986
XareltoRivaroxaban258$271,273
EntrestoSacubitril/Valsartan120$154,817
Repatha SureclickEvolocumab135$153,237
JardianceEmpagliflozin52$42,908
Praluent PenAlirocumab31$40,136
BrilintaTicagrelor31$26,688
MultaqDronedarone Hcl11$25,931
VascepaIcosapent Ethyl29$14,477
FarxigaDapagliflozin Propanediol18$13,416
Atorvastatin Calcium855$11,513
Metoprolol Succinate696$11,176
Ezetimibe273$5,168
Bumetanide131$4,104
Diltiazem 24hr Er (Cd)Diltiazem Hcl90$3,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$271,273258 claims
NovartisEntresto$1,003$154,817120 claims
AstraZenecaBrilinta, Farxiga$32$40,10449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 118 interventional cardiology providers in Wisconsin.

Other interventional cardiology in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →